Hepatocellular Cancer

P=N/A, N=40, Recruiting, The First Affiliated Hospital of Xiamen University

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

In vivo, TMEM160 knockdown suppressed tumor growth, reduced TMEM160-positive and VEGFA-positive proportions, increased interferon-γ (IFN-γ) positivity, and decreased p-PI3K/PI3K and p-AKT/AKT ratios in tumor tissues. These findings supported that TMEM160 might affect VEGFA-associated PI3K/AKT signaling to promote malignant phenotypes in HCC, suggesting TMEM160 as a candidate molecular target for further investigation.

This integrative framework combining transcriptomics, CRISPR dependency mapping, machine learning, and pharmacogenomic annotation identifies clinically relevant HB-essential genes and predictive molecular signatures for tumor identity. The derived expression-based scores provide tools for patient stratification, while drug-gene mapping highlights actionable vulnerabilities on HDAC11 with pediatric approved drugs that support rational drug repurposing strategies in hepatoblastoma.

Circulating lncRNAs exhibit high diagnostic accuracy and hold significant potential as complementary biomarkers to AFP for early HCC detection. Their mechanistic roles in tumor proliferation and immune regulation underscore their value in molecular diagnosis and personalized management of liver cancer.

P=N/A, N=600, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P=N/A, N=200, Recruiting, Bristol-Myers Squibb

P2, N=35, Recruiting, University of California, Irvine | Trial primary completion date: Jun 2026 --> Oct 2026

P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026

The precise mapping of glycosylation patterns made possible by emerging multi-omics and spatial technologies provides a clearer understanding of their mechanistic functions and translational significance. When combined, glycoprotein-based biomarkers and therapeutic targets offer new possibilities for early identification and individualised HCC treatment, hence representing a potential area for precision oncology.

It delves into its regulation of core cellular processes, its integration into oncogenic signaling networks, and its recently discovered functions in epigenetic and metabolic reprogramming. By consolidating this knowledge, we aim to highlight the multifaceted nature of DHX33 in cancer biology and firmly establish its potential as a viable and promising therapeutic target for future anticancer strategies.

Following systemic administration, FePDA-TMOC preferentially accumulates in tumors, markedly increases CD8+ T cell infiltration, elevates pro-inflammatory cytokine levels, and suppresses tumor growth and metastasis without observable systemic toxicity. By integrating ferroptosis induction with antitumor immune activation, this work highlights a rational strategy for transforming immune "cold" tumors into "hot" tumors, providing a potential nanotherapeutic approach for HCC treatment.